Take Endo USA's 2024 recall of clonazepam tablets: cartons showed 0.125 mg when the blister strips inside correctly read 0.25 mg. The FDA flagged this as a risk for accidental overdose and life-threatening respiratory depression. That's what happens when packaging and product information don't align.
Many pharma and OTC brands juggle separate vendors for blisters, cartons, and shipping cases. That fragmentation creates longer lead times and inconsistent barrier performance across formats. This guide breaks down packaging types, materials, FDA requirements, and how to choose a partner that won't leave you coordinating five different suppliers.
Key Takeaways
- Primary, secondary, and tertiary packaging each handle distinct protective and logistical jobs
- Material choice (glass, plastic, foil laminates, flexible film) determines moisture and oxygen barrier performance
- FDA and USP rules govern container closure systems, labeling accuracy, and child-resistant designs
- Flexible pouches and form-fill-seal formats fit unit-dose and powder pharmaceutical products
- A single integrated packaging partner cuts lead times and simplifies compliance documentation
What Is Pharmaceutical Packaging and Why Does It Matter?
Pharmaceutical packaging includes every material and system that encloses, protects, and informs users about a drug product, from the manufacturing line to the patient's hand. The US pharmaceutical packaging market was valued at $42.67 billion in 2025 and is projected to reach $84.68 billion by 2030, growing at a 14.7% CAGR, according to MarketsandMarkets.
Packaging serves four core functions:
- Protection from light, moisture, and oxygen that degrade active ingredients
- Tamper-evidence to signal if a product has been compromised
- Dosing accuracy through proper container design and labeling
- Regulatory information delivery via required labeling content
When packaging fails, the consequences aren't abstract. Fresenius Kabi recalled a lot of morphine sulfate injection in 2026 after mislabeled units risked containing a different opioid entirely. The FDA said the mix-up could cause life-threatening respiratory depression.
Hospira faced a similar issue with incomplete crimp seals on injectable units, creating leak risks and potential contamination.
Beyond compliance, brands now face pressure to balance protective performance with sustainability and patient convenience—a tension that's reshaping material choices across the industry.
The Three Levels of Pharmaceutical Packaging
Primary Packaging
Primary packaging touches the drug product directly, so it faces the strictest purity and barrier standards. The FDA defines primary components as anything in direct contact with the dosage form.
Common formats include:
- Blister packs and vials
- Bottles and ampoules
- Flexible pouches and sachets for powders and OTC liquids
Secondary Packaging
Secondary packaging doesn't touch the drug itself. It groups primary units together, houses patient information leaflets, and carries brand identity into retail environments.
Common formats include:
- Cartons and tablet boxes
- Shrink-sleeved bundles
- Overwraps made from plastic, paper, or laminates containing metal foil
Tertiary Packaging
Tertiary packaging handles bulk transport and warehousing: shipping cases, pallets, and stretch wrap. FDA guidance doesn't formally define this tier, but it still protects product integrity from the manufacturing floor to the pharmacy shelf.
Materials and Formats Shaping Modern Pharma Packaging
Material selection isn't cosmetic. It determines whether a drug survives its shelf life.
Common materials include:
- Glass (highest barrier, but heavier and breakable)
- HDPE/PET plastics (lightweight, cost-effective)
- Aluminum foil laminates (superior moisture/oxygen block)
- Multi-layer flexible films (customizable barrier profiles)
Why MVTR and OTR Matter
Moisture vapor transmission rate (MVTR) and oxygen transmission rate (OTR) specs determine how well a package protects against degradation. FDA guidance identifies water vapor and reactive gases as key causes of drug instability, and recommends gas-transmission and container-integrity testing where relevant.
A 2015 Packaging Digest case study illustrates this well: an initial packaging material failed under real-time stability conditions, forcing a switch to PVC/Aclar or alu/alu laminate to hit the required shelf-life target. There's no universal MVTR number. The right spec depends on the drug's sensitivity, confirmed through lab testing.
The Rise of Flexible Formats
Flexible pouches and form-fill-seal bags are expanding as space-saving alternatives to rigid packaging. Benefits include:
- Stand-up formats with tamper-evident seals
- Serialization support for track-and-trace compliance
- Smaller, lighter shipping profiles for e-commerce fulfillment
- Child-resistant reclosable options for unit-dose products
Sustainable Material Options
Brands are testing PVC-free mono-polymer blister structures using PP, PE, or PET. Amcor's AmSky blister, for instance, replaces traditional PVC/aluminum lidding with HDPE for both the lidding and the thermoformed base, earning APR Critical Guidance Recognition for its recyclability. Technical recyclability doesn't guarantee recycling at scale, so sustainability claims need real infrastructure behind them.
Material choice is only part of the compliance picture. Long-run rotogravure printing keeps branding and regulatory text color-consistent across massive production batches, which is critical when a single labeling error can trigger a recall.
FDA Regulations and Compliance Considerations
Pharmaceutical packaging must meet several core federal requirements:
- Container closure validation (21 CFR 211.94): Containers and closures must not react with, add to, or absorb the drug in ways that affect safety or purity
- Child-resistant packaging (Poison Prevention Packaging Act): Designs must resist opening by children under five while remaining usable for adults; Rx products skip CR only at explicit patient or prescriber request
- Labeling accuracy (21 CFR 211.125 and 211.130): Issued, used, and returned labels must be reconciled, with line controls that prevent mix-ups
- Tamper-evident features (21 CFR 211.132): Most retail OTC products need a visible indicator that stays intact through normal handling
USP chapters add another compliance layer:
| USP Chapter | Focus |
|---|---|
| <659> | Packaging and storage requirements |
| <661>/<661.1>/<661.2> | Plastic packaging materials and systems |
| <1663>/<1664> | Extractables and leachables testing |
Partners with ISO 9001, ISO 22000, FSSC 22000, and HACCP certifications make it easier to maintain the documentation trail regulators review in audits and stability programs.
Choosing the Right Pharmaceutical Packaging Partner
Coordinating separate vendors for blisters, pouches, and shipping cases creates friction. Every handoff adds time and introduces a new point of failure for barrier consistency.
Ken Faulhaber Packaging Solutions works as an independent sales representative connecting pharmaceutical and OTC brands directly to Formosa's integrated manufacturing network. Formosa's infrastructure includes:
- Five-layer high-speed lamination, specified to your WVTR and OTR barrier targets
- In-house bag making and thermoforming, covering trays, blisters, clamshells, and flexible pouches
- Class 10,000 cleanroom production for pharmaceutical-grade aseptic pouches
- Rotogravure printing for color-consistent labeling across long production runs
This in-house setup means fewer handoffs between production stages. Lamination, printing, bag making, and thermoforming all happen under one roof rather than across separate suppliers.
That same integration should shape how you evaluate any packaging partner. Look for:
- Responsiveness: Ken typically responds to project inquiries within one business day
- Relevant certifications: ISO 9001:2015, ISO 22000:2018, FSSC 22000, HACCP
- Format breadth: support for blisters, pouches, trays, and clamshells without adding vendors
- Forward compatibility: sustainable and recyclable options that work with your existing fill lines
Frequently Asked Questions
What are the FDA requirements for pharmaceutical packaging?
The FDA requires validated container closure systems that don't react with or degrade the drug, child-resistant packaging under the Poison Prevention Packaging Act, and accurate labeling with strict reconciliation controls.
What are the different types of packaging used in the pharmaceutical industry?
Packaging breaks into primary (direct product contact, like blisters and vials), secondary (cartons and shrink-sleeved bundles), and tertiary (shipping cases and pallets for bulk transport).
What materials are commonly used in pharmaceutical packaging?
Glass, HDPE/PET plastics, aluminum foil laminates, and multi-layer flexible films are the main options, each chosen based on required moisture and oxygen barrier performance.
How is pharmaceutical packaging different from OTC product packaging?
Both share regulatory requirements like tamper-evidence and child-resistant closures, but OTC packaging typically carries heavier retail branding and shelf-appeal demands than prescription packaging.
Why is moisture and oxygen barrier performance important in pharma packaging?
Water vapor and reactive gases are documented causes of drug degradation. Barrier performance, measured through MVTR and OTR testing, directly protects a drug's stability and shelf life.
Is flexible packaging suitable for pharmaceutical products?
Yes. Flexible pouches and form-fill-seal formats are increasingly used for unit-dose products, powders, and OTC liquids, offering tamper-evident seals and space-saving shipping profiles.
